



Last updated: September 2026

LICENSING PORTFOLIO

PRODUCT	FORM	STRENGTH	INDICATION	DOSSIER AVAILABILITY
Apraclonidine ^{New}	Ophthalmic solution	1%	Intraocular pressure	Q2 2028 (EU & UK)
Ceftaroline Fosamil ^{New}	Powder for injection	400mg 600mg	Antibiotic	Q1 2028 (EU & ANDA)
Trazoflex™ CR (breakable 12h CR trazodone tablet) ^{New}	CR tablet	75mg 150mg	Antidepressant	Q2 2027 (EU & ANDA)
Trazoflex™ XR (breakable 24h XR trazodone tablet)	XR tablet	150mg 300mg	Antidepressant	Q4 2026 (EU & ANDA)
Deslaflex™ (breakable once-a-day desvenlafaxine tablet)	Tablet	50mg 100mg 200mg	Antidepressant	Q4 2026 (EU & ANDA)
Vonoprazan	Tablet	20mg	Gastric ulcer H. pylori infection	To be confirmed (ANDA)
Avibactam-Ceftazidime	Powder for injection	0.5g + 2g	Antibiotic	Q3 2026 (EU & ANDA)
Lidocaine	Sterile jelly	2%	Pain	Dossier ready (ANDA)
Timolol	Ophthalmic solution	0.25% 0.50%	Glaucoma	Dossier ready (ANDA)
Timolol + Dorzolamide	Ophthalmic solution	2% + 0.5%	Glaucoma	Dossier ready (ANDA)
Lifitegrast	Ophthalmic solution	5%	Dry eye	Dossier ready (ANDA)
Prednisolone	Ophthalmic suspension	1%	Eye inflammation	Q2 2027 (ANDA)
Brinzolamide	Ophthalmic suspension	1%	Glaucoma	Q4 2026 (ANDA)
Brinzolamide + Brimonidine	Ophthalmic suspension	1% + 0.2%	Glaucoma	To be confirmed (ANDA)
Idebenone	Tablet	150mg	Optic neuropathy	Dossier ready (EU)
Dexmedetomidine*	Solution for injection	100mcg/ml	Sedative	Dossier ready (US & EU)
Fosphenytoin	Concentrate for solution injection	75mg/ml	Antiepileptic	Dossier ready (EU)
Isosorbide mononitrate	SR tablets	30mg	Cardiovascular	Dossier ready (EU)
Nystatin	Oral suspension	100000 IU/ml	Antifungal	Dossier ready (EU)
Piperacillin/Tazobactam	Powder for injection	2g/250mg 4g/500mg	Antibiotic	Dossier ready (EU)
Tafluprost	Ophthalmic solution	0.0015%	Glaucoma	Dossier ready (EU)

*Vertically integrated. In-house API.

Products will not be supplied prior to expiry of relevant conflicting patents in the territory.

About us: Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees. Recipharm provides expertise in development and manufacturing across oral dosage sterile, fill & finish, and biologics; clinical trial material development and manufacturing services; and, pharmaceutical product development. Its Biologics segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical and commercial development and manufacture for new biological modalities. The company operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For further information please contact:

Business Development department, RPH Pharmaceuticals
bd.rph@recipharm.com

recipharm.com